Description
As part of the MAIA consortium, CATAG has developed the MAIA toolkit Optimising implementation of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). This toolkit will assist Medicines and Therapeutics Committees to enhance the understanding and implementation of GDMT for managing HFrEF.
This toolkit consists of:
- Optimising implementation of guideline-directed medical therapy for heart failure with reduced ejection fraction practice tool for Medicines and Therapeutics Committees.
- Optimising management of heart failure with reduced ejection fraction with quadruple therapy teaching tool for clinical educators.
Key messages
- Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection
fraction (HFrEF) recommends quadruple therapy with a renin-angiotensin system
inhibitor, heart-failure specific beta blocker, mineralocorticoid receptor antagonist
(MRA), and sodium-glucose co-transporter 2 inhibitor (SGLT2), unless contraindicated. - Quadruple therapy has greater cumulative benefits offering rapid and significant
improvements in morbidity and mortality. - Discharge summaries should communicate:
- left ventricular ejection fraction (LVEF) in patients with heart failure.
- The plan for medicines initiation and titration.
- contraindications/intolerances to quadruple therapy.
- the need for GP review within 7 days post-discharge
- Medicines and Therapeutics Committees (MTCs) are advised to identify and review
barriers to the implementation of GDMT and facilitate quality improvement strategies
such as heart failure stewardship program.